CompletedPhase 3

A Phase 3 Clinical Study of KHK 4827

Japan155 participantsStarted 2014-02

Plain-language summary

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject has voluntarily signed the written informed consent form to participate in this study * Subject has completed the week 52 evaluation either in Study 003 or 004 Exclusion Criteria: * Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration) * Subject has been judged to be ineligible for participation in the study by the investigators/sub investigators

What they're measuring

Incidence and types of adverse events and adverse reactions

Timeframe: 28 weeks

Anti-KHK4827 antibody

Timeframe: 28 weeks

Trial details

NCT IDNCT02052609

SponsorKyowa Kirin Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-01-28

View on ClinicalTrials.gov More Psoriasis Vulgaris trials